How are new fludarabine conditioning combinations impacting transplant outcomes?
AML Hub
English - April 22, 2022 11:42 - 6 minutes - 8.35 MBEducation aml Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes?
Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used and why. Finally, Gavriilaki outlines different studies presented at EBMT covering fludarabine combinations for patients with AML and MDS.
Hosted on Acast. See acast.com/privacy for more information.